Accumulating body of evidence suggest that the incidence rate of gynecological tumors is rapidly increasing over time. Gynecological oncology comprises a heterogeneous cluster of malignancies, such as the tumors of the endometrium, ovary, cervix, and vulva. The primary treatment of the vast majority of gynecological cancers is surgery. Unfortunately, the procedures of gynecological oncology are often complex and associated with high morbidity rates reaching up to as high as 90%. Such morbidities are undesirable and represent a paramount matter for both the gynecological oncology physicians and patients. Moreover, these morbidities greatly have a negative impact on the utilization of healthcare resources. Therefore, it is critically important to identify those patients who may likely benefit from particular perioperative interventions to minimize such gynecological oncology related morbidities.
These gynecological oncology related morbidities can take place before, during, or after the surgical intervention. Sometimes, prior to undergoing the frontline surgical intervention, some gynecological oncology patients may undergo select preoperative procedures, such as hysteroscopy, colposcopy, hysterosalpingogram, just to name a few. Such procedures themselves can often associate with additional morbidities before the surgical intervention, such as pain, infections, and iatrogenic injuries. Furthermore, some select gynecological procedures, such as aggressive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), often associate with heightened hazards of morbidities, and such interventions are often of a special concern to the operating surgeons and patients alike.
In this special issue, we look forward to exciting research investigations geared toward minimizing morbidity in gynecological oncology. Specifically, areas of research should focus on novel technical advances and pharmacological agents to reduce a wide array of morbidities in gynecological oncology, such as intraoperative blood loss, postoperative pain control, infection, intragenic injures to important structures (for example ureter), and cosmetic outcomes. Notably, the scope of this special issue is broad and includes surgeries (such as: hysterectomy, cystectomy, CRS, HIPEC, single-port laparoscopy, etcetera) as well as preoperative procedures (such as: hysteroscopy, colposcopy, hysterosalpingogram, etcetera). Additionally, this issue will include studies about minimally invasive surgery and how it can decrease morbidity of gynecological oncology. Lastly, we welcome any contributions that may directly or indirectly minimize morbidity in gynecological oncology, inclusive of adjuvant chemotherapeutic regimens. All types of manuscripts are welcome, including full-length articles, short communications, narrative reviews, systematic reviews and meta-analyses, case reports, and special contributions.
Dr. Ahmed Abu-Zaid and Dr. Osama Alomar
Manuscripts should be submitted via our online editorial system at https://jour.ipublishment.com/imr/access/login by registering and logging in to this website. Once you are registered, click here to start your submission Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted papers should be well formatted and use good English.